Sara Bonstein Sells 57,765 Shares of Insmed, Inc. (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 57,765 shares of the business's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $101.78, for a total transaction of $5,879,321.70. Following the transaction, the chief financial officer now owns 93,536 shares in the company, valued at $9,520,094.08. This represents a 38.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, June 10th, Sara Bonstein sold 57,766 shares of Insmed stock. The shares were sold at an average price of $89.12, for a total transaction of $5,148,105.92.
• On Tuesday, June 3rd, Sara Bonstein sold 1,579 shares of Insmed stock. The shares were sold at an average price of $71.50, for a total transaction of $112,898.50.
• On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total transaction of $107,206.74.
• On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total transaction of $601,474.70.

Insmed Price Performance

INSM traded down $2.25 during trading on Friday, reaching $99.49. 34,467,302 shares of the company traded hands, compared to its average volume of 2,309,118. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $106.83. The firm has a fifty day simple moving average of $78.01 and a 200 day simple moving average of $75.54. The company has a market cap of $18.87 billion, a P/E ratio of -16.72 and a beta of 0.80.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The company had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. During the same period last year, the business earned ($1.06) earnings per share. The company's quarterly revenue was up 22.9% compared to the same quarter last year. On average, equities analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Sowell Financial Services LLC purchased a new position in shares of Insmed in the first quarter valued at $255,000. M&T Bank Corp grew its holdings in shares of Insmed by 5.6% in the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock valued at $217,000 after purchasing an additional 166 shares in the last quarter. Truist Financial Corp grew its holdings in shares of Insmed by 3.4% in the fourth quarter. Truist Financial Corp now owns 30,038 shares of the biopharmaceutical company's stock valued at $2,074,000 after purchasing an additional 1,000 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in shares of Insmed in the fourth quarter valued at $1,864,000.

Analyst Ratings Changes

INSM has been the topic of several research analyst reports. Bank of America upped their target price on shares of Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Royal Bank Of Canada upped their target price on shares of Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Citigroup upgraded shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. Morgan Stanley increased their price objective on shares of Insmed from $90.00 to $102.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 11th. Finally, Leerink Partners increased their target price on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $106.80.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.